Efficacy and Safety of Ongericimab in Patients With Dyslipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials With GRADE Assessment.
Dyslipidemia is a major modifiable risk factor for atherosclerotic cardiovascular disease, and many high-risk patients do not reach target low-density lipoprotein cholesterol (LDL-C) levels despite conventional therapy. Ongericimab is a humanized monoclonal antibody against proprotein convertase subtilisin/kexin type 9...